ReviewMetabolites2018
Current Applications of Metabolomics in Cirrhosis.
Review in Metabolites, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Transhepatic Gradients Reveal Selective Hepatic Processing Defects With Systemic Consequences in Cirrhosis.Comprehensive physiology · 2026Article
- Characterization of theInternational journal of molecular sciences · 2026Article
- Characterization of theInternational journal of molecular sciences · 2026Article
- Combined Approach of Chromatographic Fractionation and Raman Spectroscopy for Metabolite Profiling ofInternational journal of molecular sciences · 2026Article
- Particularly strong immune response to influenza vaccination in patients with decompensated liver cirrhosis linked to systemic inflammation.Frontiers in immunology · 2026Observational
- Investigating the causal role of serum metabolites in substance use disorder risk: a study integrating Mendelian randomization and synthesis analysis.Discover mental health · 2025Article
- Metabolomic discoveries for early diagnosis and traditional Chinese medicine efficacy in ischemic stroke.Biomarker research · 2024Review
- Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.International journal of molecular sciences · 2022Review
- The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective.Frontiers in medicine · 2022Review
- Review
- Serum and urinary metabolomics and outcomes in cirrhosis.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Metabolomics is the identification and quantification of all or specified metabolites in a living system under a specific condition or disease. Metabolomics in cirrhosis can be used in diagnosing complications, determining prognosis and assessment of response to therapy. In this review, we summarized representative applications of metabolomics in cirrhosis and significant metabolites associated with cirrhosis and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.